Cargando…
Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis
Sarcopenia is a major public health issue that affects older adults. Myostatin inhibitory-D-peptide-35 (MID-35) can increase skeletal muscle and is a candidate therapeutic agent, but a non-invasive and accessible technology for the intramuscular delivery of MID-35 is required. Recently, we succeeded...
Autores principales: | Michiue, Kohki, Takayama, Kentaro, Taniguchi, Atsuhiko, Hayashi, Yoshio, Kogure, Kentaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058260/ https://www.ncbi.nlm.nih.gov/pubmed/36986496 http://dx.doi.org/10.3390/ph16030397 |
Ejemplares similares
-
Iontophoresis of Biological Macromolecular Drugs
por: Hasan, Mahadi, et al.
Publicado: (2022) -
Peptide‐2 from mouse myostatin precursor protein alleviates muscle wasting in cancer‐associated cachexia
por: Ojima, Chiharu, et al.
Publicado: (2020) -
Transdermal Delivery by Iontophoresis
por: Rawat, Swati, et al.
Publicado: (2008) -
The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy
por: Ohsawa, Yutaka, et al.
Publicado: (2015) -
Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
por: Hanada, Kako, et al.
Publicado: (2022)